An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization

Inclusion Criteria: * Signed the informed consent form, volunteered to participate in the trial and followed up according to the protocol. * Ages from 18 to 75,male or female. * Superficial or deep neovascularization induced by trauma/chemical burn/inflammation/corneal transplantation. Exclusion Criteria: * Subjects who had significant defect in the corneal epithelium. * Study eye had been injected of anti-vegf drugs within 3 months before screening * Study eye was performed surgery (except keratoplasty) within 3 months prior screening, or eye surgery was planned during this trial period. * Oral glucocorticoid administration within 1 month prior screening (except for duration less than 7 days) * Systemic use of anti-vegf drugs within 45 days prior to screening. * Have history of abnormal coagulation, such as end-stage liver disease, or are taking anticoagulants（except aspirin）. * Uncontrolled clinical problems such as canner etc.. * Unable or unwilling to use effective contraception. * Positive blood tests for pregnancy (female subjects) * Participated in drug clinical trials within 3 months before the first administration. * The researchers think the participants were not suitable for this trail.